Source comparison
Thymosin Alpha-1 Studied Autoimmune Research: Treatment Comparison
Before writing this table, we analysed how thymosin alpha-1 differs mechanistically from established autoimmune therapies. The distinctions matter. Peptides, biologics, and small molecules operate on entirely different immune axes. Thymosin Alpha-1 (Peptide) T
This comparison does not assign a generated winner or score.
- Before writing this table, we analysed how thymosin alpha-1 differs mechanistically from established autoimmune therapies. The distinctions matter. Peptides, biologics, and small molecules operate on entirely different immune axes.
- Thymosin Alpha-1 (Peptide)
- TLR2 agonist → Treg expansion → cytokine modulation
- 1.6mg SC twice weekly
- RA, SLE, psoriasis (adjunctive)
- 15–25% improvement beyond standard care
- Modulates rather than suppresses. Additive benefit when conventional therapy plateaus, but not monotherapy-grade efficacy
- TNF-α Inhibitors (Biologics)
- Direct cytokine blockade. Binds TNF-α preventing receptor activation
- Weekly to monthly injection or infusion
- RA, psoriatic arthritis, IBD, ankylosing spondylitis
- ACR50 response 40–60% in RA; remission rates 20–35%
- Gold standard for moderate-to-severe disease. Rapid onset but requires infection screening and carries reactivation risk
- Methotrexate (Small Molecule)
- Inhibits dihydrofolate reductase → suppresses T-cell proliferation
- 15–25mg oral or SC weekly
- RA (first-line), psoriatic arthritis, SLE
- ACR20 response 50–65% in RA as monotherapy
- Cornerstone therapy. Well-tolerated at correct doses but requires folic acid supplementation and liver monitoring
- JAK Inhibitors (Small Molecule)
- Intracellular kinase inhibition → blocks multiple cytokine pathways
- Daily oral dosing
- RA, psoriatic arthritis, UC, atopic dermatitis
- ACR50 response 30–50% in RA; clinical remission 15–25%
- Broad immune suppression. Effective but carries infection and thrombosis warnings per FDA black box
- Corticosteroids
- Broad glucocorticoid receptor activation → systemic immune suppression
- Variable. Taper protocols standard
- All autoimmune conditions (bridge therapy)
- Rapid symptom control 70–90% but unsustainable long-term
- Essential for flares. Not viable maintenance due to metabolic and bone density consequences beyond 3 months